先前的研究表明,双膦酸盐(BP)可以改善牙周病,因为它们具有抗骨质疏松症的特性。体外研究表明,BP诱导细胞毒性,抑制伤口愈合,从而影响牙周病。Denosumab和BPs有替代适应症。BP和denosumab与牙龈疾病无关。我们通过对美国FDA不良事件报告系统(FAERS)数据库中的数据应用贝叶斯和非比例分析来评估这种关系。该研究分析了BP和denosumab报告的事件,并在狭窄的牙龈疾病标准化MedDRAQueries中找到了首选术语。总共有5863例报告的牙龈疾病与5个BP(阿仑膦酸盐,帕米膦酸盐,伊班膦酸钠,利塞膦酸盐,和唑来膦酸)和地诺单抗。超过15%的与BPs和除denosumab以外的denosumab相关的牙龈疾病患者在短期或长期住院。我们的发现表明BP和denosumab具有显著的报告优势比(ROR),比例报告比率(PRR),和关于牙龈疾病的信息成分(IC)。帕米膦酸盐具有最高的相关性(ROR=64.58,PRR=57.99,IC=5.71),而与denosumab的相关性最弱(ROR=3.61,PRR=3.60,IC=1.77)。发现六种药物与牙龈疼痛之间存在显着关联,牙龈衰退,牙龈炎,牙周病,和牙周炎。总之,我们对相关性的全面概述,临床特征,BPs和与denosumab相关的牙龈疾病的预后表明,这些问题值得继续监测和适当管理。
Prior research has indicated that bisphosphonates (BPs) can improve periodontal disease because of their anti-osteoporosis properties. In vitro studies have shown that BPs induce cytotoxicity, inhibit wound healing, and thus affect periodontal disease. Denosumab and BPs have alternative indications. BP and denosumab are not known to correlate with gingival disorders. We assessed such a relationship by applying Bayesian and nonproportional analyses to data in the US FDA Adverse Event Reporting System (FAERS) database. The study analyzed BPs and denosumab-reported incidents with preferred terms found in the narrow Standardized MedDRA Queries for gingival disorders. A total of 5863 reported cases of gingival disorders were associated with five BPs (alendronate, pamidronate, ibandronate, risedronate, and zoledronate) and denosumab. More than 15% of patients with gingival disorders related to BPs and denosumab other than denosumab were hospitalized over short- or long-term periods. Our findings indicated BPs and denosumab had significant reporting odds ratios (ROR), proportional reporting ratios (PRR), and information components (IC) with respect to gingival disorders. Pamidronate had the highest association (ROR = 64.58, PRR = 57.99, IC = 5.71), while the weakest association was found with denosumab (ROR = 3.61, PRR = 3.60, IC = 1.77). Significant associations were found between the six drugs and gingival pain, gingival recession, gingivitis, periodontal disease, and periodontitis. In conclusion, our comprehensive overview of the correlations, clinical characteristics, and prognoses of BPs and denosumab-related gingival disorders suggests that these issues deserve continued surveillance and appropriate management.